Bharat Immunological & Biological Corporation Ltd. (BIBCL) is an Indian pharmaceutical company that produces pharmaceutical formulations, such as Oral Polio Vaccine, Hepatitis B vaccine, zinc tablets, and sanitizers. The company was incorporated in 1989 in Uttar Pradesh.
BIBCL went public in 1994 and listed its shares on Delhi, Mumbai, and Kanpur stock exchanges. The Bombay Stock Exchange has allotted the number 524663 to BIBCL. As of March 31, 2022, the company’s total market capitalisation is at Rs. 121.34 crore. Bharat Biotech share price as of the same date was Rs. 28.10. Bharat Biotech stock price hit a 52-week high of Rs. 94.50 and recorded a 52-week low of Rs. 28. The latest price to book ratio of Bharat Immunological shares was at 0.88 as of March 31, 2022.
The pharmaceutical company has a number of worthy milestones. In 1996, BIBCL started bulk production of Oral Polio Vaccines. It received its WHO-GMP certification in 1999. The next year, Bharat Immunological & Biological Corporation Ltd. bagged an order from UNICEF and the Ministry of Health and Family Welfare, Government of India for 170 million doses. In 2001, the company bagged another vaccine order of 270 million doses from UNICEF and the Ministry of Health and Family Welfare.
In 2006, the company made it to the list of top 20 biotech companies in India for its performance. Since 2007, BIBCL has launched a number of other products, including zinc tablets for treating diarrhoea among young children, diarrhoea treatment kits, bivalent oral polio vaccine, and therapeutic food.
For the quarter ended December 31st 2021, Bharat Immunological & Biological Corporation Ltd. posted total revenues of Rs. 17.43 crores. For the same period in the previous year, the company posted revenues of Rs. 25.20 crores. BIBCL recorded a loss of Rs. 0.33 crores for the quarter ended December 31st 2021. For the same period in the previous year, the company recorded a total loss of Rs. 1.90 crores. Bharat Immunological & Biological Corporation Ltd. posted earnings per share of -Rs.0.08 for the quarter ended December 31st 2021 compared to -Rs. 0.44 for the same period in the previous year.
Disclaimer:- ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: email@example.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.